R. & D. Biocagency Laboratories Group

Biocogency appears to be a private Cyprus-registered life sciences holding company operating under the formal name R. & D. Biocogency Laboratories Inc. Ltd. Publicly available information is sparse, but transaction disclosures and press releases describe it as having a portfolio spanning generic pharmaceuticals, nuclear medicine products and equipment, biotechnology research, and vivarium laboratory capabilities. The company is best documented through its 2020 acquisition of majority control of Rafarma Pharmaceuticals, which it described as part of a broader strategy to expand its biotechnology footprint into North America. Available evidence suggests Biocogency is more of an operating investment and portfolio-management group than a single-product therapeutic developer. Because there is no clearly available current corporate website or detailed pipeline disclosure, its specific R&D programs, targets, and development stages cannot be reliably confirmed from primary public sources.